Anti‐angiogenesis agent DS‐4152 is a potent and selective inhibitor of HIV‐1 replicationin vitro
作者:
Masanori Baba,
Shiro Shigeta,
Tohru Ikeuchi,
Hiroshi Korenaga,
Yasuaki Osada,
期刊:
AIDS
(OVID Available online 1994)
卷期:
Volume 8,
issue 1
页码: 43-48
ISSN:0269-9370
年代: 1994
出版商: OVID
关键词: Kaposi's sarcoma;chemotherapy;sulfated polysaccharide;HIV-1;antiviral activity
数据来源: OVID
摘要:
ObjectiveTo determine whether the anti-angiogenesis agent DS-4152 inhibits the replication of HIV-1in vitro.DesignA sulfated polysaccharide-peptidoglycan DS-4152 has recently been identified as a potent and selective inhibitor of Kaposi's sarcoma (KS). Therefore, it is important to evaluate the anti-HIV-1 activity of DS-4152 alone and in combination with dideoxynucleosides.MethodsActivity of DS-4152 against HIV-1 replication was examined in MT-4, Molt-4, and peripheral blood lymphocyte cells. The inhibitory effect of the compound on syncytium-formation was determined by cocultivation of Molt-4 cells with Molt-4/IIIbcells. Inhibition of virus adsorption to the host cells was measured by a p24antigen capture enzyme-linked immunosorbent assay.ResultsDS-4152 showed potent and selective inhibition of HIV-1 replication in the cell systems. Its 50% effective concentration for HIV-1 (IIIBstrain) in MT-4 cells was 0.7μg/ml. The compound was not cytoxic at concentrations ≤ 100 μg/ml. DS-4125 proved inhibitory to syncytium-formation and virus adsorption. The anti-HIV-1 activities of zidovudine, dideoxycytidine and dideoxyinosine were not affected by the presence of DS-4152.ConclusionDS-4152 has the potential, from thesein vitrostudies, to function as an anti-HIV-1 as well as an anti-angiogenesis agent. In order to determine this possibility, consequences of DS-4152 infusion on HIV-1 p24serum levels and CD4+cell counts over time are being examined in ongoing clinical trials in the United States on patients with AIDS-associated KS.
点击下载:
PDF
(429KB)
返 回